FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1092-1094 April 14, 1994 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Congenital erythropoietic porphyria is a rare autosomal recessive disorder with progressive photomutilation and hemolysis due to excessive porphyrin production. Published studies have shown that oral treatment with activated charcoal to absorb intraluminal porphyrins in the intestine was effective in reducing the porphyrin concentration and clinical symptoms in three patients^1,2,3. Efficacy over a prolonged period was reported in one patient¹.

A 44-year-old patient with clinically and biochemically confirmed congenital erythropoietic porphyria was treated with two different brands of charcoal emulsion for a total of 32 days. One brand had been used with success in a previously . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.